Evotec invests in Carrick Therapeutics

German biotech firm Evotec (EVT: Xetra) says that, in line with its strategy to participate in promising corporate formations it will deepen its already existing relationship with Carrick Therapeutics.

Evotec will invest up to $6 million towards Carrick's latest funding round. The total $95 million round was led by ARCH Venture Partners and Woodford Investment Management with participation from Cambridge Enterprise Seed Funds, Cambridge Innovation Capital, Google Ventures, Lightstone Ventures and Evotec.

Carrick, headquartered in Dublin, Ireland, with R&D located in Oxford and Dublin has a clear vision for cancer patients: Its mission is to target the molecular pathways that drive the most aggressive and resistant forms of cancer in order to have a major impact on the lives of patients. Instead of banking on a single compound or biological mechanism, Carrick is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient's tumour. To support this mission Evotec will provide its full range of discovery and oncology services, through its discovery and pre-clinical platform. Carrick will progress multiple programs through hit-to-lead and lead optimization with the goal of delivering multiple development candidates.